.Attribute Medication, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a mean consequence of 11 months, clients along with metastatic gastrointestinal cysts who got biomarker-matched therapies based on spreading cyst DNA profiling revealed a better clinical perk than those acquiring unmatched treatment.